Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Acquisitions | $19,956 | 1 | 58.1% |
| Current or prospective ownership or investment interest | $14,317 | 6 | 41.7% |
| Food and Beverage | $92.43 | 3 | 0.3% |
| Unspecified | $0 | 7 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| US Retina LLC | $34,273 | 14 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $68.76 | 1 | $0 (2024) |
| Genentech USA, Inc. | $23.67 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $68.76 | 1 | Regeneron Healthcare Solutions, Inc. ($68.76) |
| 2023 | $19,956 | 2 | US Retina LLC ($19,956) |
| 2022 | $5,577 | 3 | US Retina LLC ($5,577) |
| 2021 | $4,744 | 4 | US Retina LLC ($4,732) |
| 2020 | $1,734 | 2 | US Retina LLC ($1,734) |
| 2019 | $2,274 | 2 | US Retina LLC ($2,274) |
| 2018 | $0 | 1 | US Retina LLC |
| 2017 | $12.09 | 2 | Genentech USA, Inc. ($12.09) |
All Payment Transactions
17 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/18/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $68.76 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/13/2023 | US Retina LLC | — | Acquisitions | Cash or cash equivalent | $19,956.00 | General |
| 2023 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 04/13/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $4,849.34 | General |
| 04/12/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $727.42 | General |
| 2022 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 06/11/2021 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $11.58 | General |
| Category: Ophthalmology | ||||||
| 05/11/2021 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $4,109.09 | General |
| 05/06/2021 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $623.21 | General |
| 2021 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 03/13/2020 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $1,733.85 | General |
| 2020 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 02/21/2019 | US Retina LLC | — | Current or prospective ownership or investment interest | Stock option | $2,273.83 | General |
| 2019 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 2018 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 06/12/2017 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $12.09 | General |
| Category: Ophthalmology | ||||||
| 2017 | US Retina LLC | — | — | — | $0.00 | Ownership |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 13 | 2,919 | 7,010 | $1.4M | $1.0M |
| 2020 | 14 | 3,695 | 10,714 | $2.3M | $1.7M |
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2021 | 203 | 2,391 | $799,140 | $592,282 | 74.1% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2021 | 36 | 248 | $235,270 | $177,851 | 75.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 365 | 909 | $81,908 | $57,234 | 69.9% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 662 | 703 | $88,575 | $54,252 | 61.2% |
| 67028 | Injection of drug into eye | Office | 2021 | 251 | 649 | $121,020 | $54,188 | 44.8% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 445 | 1,011 | $41,924 | $29,440 | 70.2% |
| 92250 | Photography of the retina | Office | 2021 | 692 | 812 | $32,508 | $21,035 | 64.7% |
| 92004 | Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits | Office | 2021 | 73 | 73 | $11,096 | $7,382 | 66.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 58 | 58 | $9,711 | $5,919 | 61.0% |
| 67228 | Laser destruction of leaking retinal blood vessels, 1 or more sessions | Office | 2021 | 14 | 21 | $8,859 | $5,635 | 63.6% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2021 | 77 | 91 | $7,943 | $5,425 | 68.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 27 | 27 | $3,505 | $2,328 | 66.4% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 16 | 17 | $959.67 | $745.57 | 77.7% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2020 | 251 | 4,071 | $1.4M | $1.1M | 75.7% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2020 | 44 | 320 | $299,622 | $237,566 | 79.3% |
| 67028 | Injection of drug into eye | Office | 2020 | 303 | 1,057 | $176,854 | $81,478 | 46.1% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2020 | 829 | 956 | $120,830 | $80,190 | 66.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 414 | 1,185 | $88,373 | $63,577 | 71.9% |
| 92250 | Photography of the retina | Office | 2020 | 902 | 1,223 | $55,559 | $39,317 | 70.8% |
| 92134 | Diagnostic imaging of retina | Office | 2020 | 476 | 1,340 | $51,079 | $37,512 | 73.4% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 172 | 172 | $28,500 | $19,396 | 68.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 123 | 166 | $18,410 | $12,309 | 66.9% |
| 67228 | Laser destruction of leaking retinal blood vessels, 1 or more sessions | Office | 2020 | 15 | 30 | $10,334 | $7,752 | 75.0% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2020 | 96 | 119 | $10,425 | $7,395 | 70.9% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 35 | 40 | $1,772 | $1,309 | 73.9% |
About Dr. Serge Debustros, MD
Dr. Serge Debustros, MD is a Ophthalmology healthcare provider based in Harvey, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/22/2005. The National Provider Identifier (NPI) number assigned to this provider is 1962402685.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Serge Debustros, MD has received a total of $34,365 in payments from pharmaceutical and medical device companies, with $68.76 received in 2024. These payments were reported across 17 transactions from 3 companies. The most common payment nature is "Acquisitions" ($19,956).
As a Medicare-enrolled provider, Debustros has provided services to 6,614 Medicare beneficiaries, totaling 17,724 services with total Medicare billing of $2.7M. Data is available for 2 years (2020–2021), covering 27 distinct procedure/service records.
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist, Retina Specialist
- Location Harvey, IL
- Active Since 07/22/2005
- Last Updated 02/04/2022
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1962402685
Products in Payments
- EYLEA HD (Biological) $68.76
- Lucentis (Biological) $23.67
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Harvey
Mathew Maccumber, Md, MD
Ophthalmology — Payments: $248,259
Kourous Rezaei, Md, MD
Ophthalmology — Payments: $98,698
David Orth, Md, MD
Ophthalmology — Payments: $70,789
Timothy Flood, Md, MD
Ophthalmology — Payments: $57,253
Dr. Vivek Chaturvedi, M.d, M.D
Ophthalmology — Payments: $48,512
Sohail Hasan, Md, MD
Ophthalmology — Payments: $30,975